卡非佐米、泊马度胺和地塞米松联合或不联合达雷妥尤单抗治疗复发多发性骨髓瘤的1/2期研究
这项1/2期研究评估卡非佐米、泊马度胺和地塞米松(KPd)及联合达雷妥尤单抗(Dara-KPd)治疗复发/难治多发性骨髓瘤。KPd最大耐受剂量组4周期后总缓解率为79%(95%CI 62%-91%),Dara-KPd组4周期后近完全缓解或更好率为39%(95%CI 22%-59%),均达到疗效统计阈值。Dara-KPd诱导更深更持久缓解且未影响安全性,作者认为需进一步评估该四药方案。
要点
- KPd最大耐受剂量为卡非佐米20/27 mg/m2特定日期给药、泊马度胺4 mg第1-21天、地塞米松40 mg每周。
- KPd最大耐受剂量组4周期后总缓解率79%(95%CI 62%-91%),达到疗效统计阈值。
- Dara-KPd组4周期后近完全缓解或更好率39%(95%CI 22%-59%),达到疗效统计阈值。
核心结论
- Dara-KPd在主要为高危、来那度胺难治人群中诱导比KPd更深更持久的缓解,且未影响安全性,作者认为需进一步评估该四药方案。
研究设计与样本
- 1/2期研究,评估KPd和Dara-KPd治疗复发/难治多发性骨髓瘤。
- 1期主要终点为确定KPd最大耐受剂量,2期主要终点分别为KPd和Dara-KPd4周期后总缓解率和近完全缓解率。
- 66例患者接受KPd,其中34例在最大耐受剂量;28例接受Dara-KPd。
主要发现
- KPd最大耐受剂量组4周期后总缓解率为27/34(79%;95%CI 62%-91%),达到疗效统计阈值。
- KPd中位随访44个月时,中位无进展生存期13个月,总生存期44个月。
- Dara-KPd组4周期后近完全缓解或更好率为11/28(39%;95%CI 22%-59%),达到疗效统计阈值。
- Dara-KPd最佳缓解时总缓解率为25/28(89%),流式细胞术(10-5)可测量残留病阴性率为17/26(65%)。
- Dara-KPd中位随访26个月时,中位无进展生存期和总生存期均未达到。
关键数值与推荐
- KPd最大耐受剂量:卡非佐米20/27 mg/m2,第1、2、8、9、15、16天(第1-8周期)及第9周期及以后第1、2、15、16天给药;泊马度胺4 mg口服第1-21天;地塞米松40 mg口服每周,28天为一周期。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论提出需进一步评估该四药方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We conducted a phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) and KPd with daratumumab (Dara-KPd) in relapsed/refractory multiple myeloma. The primary end points were identification of a maximum tolerated dose (MTD) of KPd for phase 1, and rates of overall response (ORR) and near complete response (nCR) after 4 cycles of KPd and Dara-KPd, respectively, for phase 2. The MTD for KPd was carfilzomib 20/27 mg/m2 on days 1, 2, 8, 9, 15, and 16 (cycles 1-8) and days 1, 2, 15, and 16 for cycles 9 and beyond; oral pomalidomide 4 mg on days 1 to 21; and oral dexamethasone 40 mg weekly in 28-day cycles. Sixty-six patients received KPd, including 34 at the MTD. The ORR after 4 cycles of KPd at the MTD was 27/34 (79%; 95% confidence interval [CI], 62%-91%), meeting the statistical threshold for efficacy. At a median follow-up of 44 months, the median progression-free survival (PFS) was 13 months and overall survival (OS) 44 months. Twenty-eight patients received Dara-KPd. The rate of nCR or better after 4 cycles was 11/28 (39%; 95% CI, 22%-59%), meeting the statistical threshold for efficacy. As the best response to Dara-KPd, the ORR was 25/28 (89%) and the rate of measurable residual disease negativity by flow cytometry (10-5) was 17/26 (65%). At a median follow-up of 26 months, the median PFS and OS for Dara-KPd were not reached. Dara-KPd induced deeper and more durable responses than KPd without compromising safety in a predominantly high-risk, lenalidomide-refractory population, warranting further evaluation of this quadruplet. This trial is registered at www.clinicaltrials.gov as #NCT01665794.
引用
- Derman BA, Zonder J, Reece D, et al. Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma. Blood Adv. 2023. PMID: 36763537. doi:10.1182/bloodadvances.2022008866
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。